The metabolism of oxygen in aerobic organisms leads to generation of reactive oxygen species (ROS). These entities are able to oxidize almost all classes of macromolecules, including proteins, lipids and nucleic acids. The physiological level of ROS is usually regulated by antioxidant defense mechanisms. There are at least three groups of antioxidant enzymes: superoxide dismutases, catalases and glutathione peroxidases (GSH-Pxs) which neutralize ROS. The trace elements (copper, zinc and selenium) bound to the active sites of the above listed enzymes play an important role in the antioxidant defense system. In mammals, a major function of selenium (Se) and Se-dependent GSH-Pxs is to protect cells from oxidative stress. Selenium concentrations and GSH-Px activities are altered in blood components of chronic kidney disease (CKD) patients. The Se level is frequently lower than in healthy subjects and the concentration very often decreases gradually with advancing stage of the disease. Studies on red cell GSH-Px activity in CKD patients reported its values significantly lower, significantly higher and lower or higher, but not significantly as compared with healthy subjects. On the other hand, all authors who studied plasma GSH-Px activity have shown significantly lower values than in healthy subjects. The degree of the reduction decreases gradually with the progression of the disease. High inverse correlations were seen between plasma GSH-Px activity and creatinine level. A gradual decrease in plasma GSH-Px activity in CKD patients is due to the fact that this enzyme is synthesized predominantly in the kidney and thus the impairment of this organ is the cause of the enzyme's lower activity. Se supplementation to CKD patients has a slightly positive effect in the incipient stage of the disease, but usually no effect was observed in end-stage CKD. Presently, kidney transplantation is the only treatment that may restore plasma Se level and GSH-Px activity in patients suffering from end-stage CKD. A few studies have shown that in kidney recipients, plasma Se concentration and GSH-Px activity are restored to normal values within a period of 2 weeks to 3 months following surgery and thus it can be acknowledged that Se supplementation to those patients has a positive effect on plasma GSH-Px activity.
InTRODuCTIOn
In normal physiological conditions, the metabolism of oxygen in aerobic organisms leads to the generation of dangerous and very reactive compounds, known as free radicals or reactive oxygen species (ROS) (Meier, 2001; Lim et al., 2002) , including superoxide radical (O 2
•− ) and hydroxyl radical (OH • ) (Fantel, 1996; Castro & Freeman, 2001; Young & Woodside, 2001) . Some authors consider hydrogen peroxide (H 2 O 2 ) as a free radical, although it is not one (Castro & Freeman, 2001) , as it can easily 664 2006 B.A. Zachara and others cross cell membranes and in the presence of transition metals (e.g. iron or copper) can be reduced to OH • , the strongest oxidant generated in biological systems (Jamieson, 1989; Fantel, 1996) . Free radicals are able to oxidize almost all classes of biologically important macromolecules, including proteins, lipids and nucleic acids (Halliwell & Gutteridge, 1989) . The physiological level of oxidants is usually regulated by antioxidant defense mechanisms, both endogenous and exogenous, which control the flux of ROS through specific scavenger reactions and detoxification pathways (Galli et al., 1999; Baynes & Thorpe, 1999 ). An elevated level of ROS and/or reduced antioxidant activity result in increased oxidative stress, which has been implicated in the pathology of several diseases, such as tumor development, viral expression (HIV, AIDS), neurological diseases (Alzheimer's, Parkinson's), diabetes mellitus, atherosclerosis, hypertension, and chronic kidney disease (CKD) (Marx, 1987; Meier, 2001) . The antioxidant defense system can be divided into two major groups: endogenous mechanisms (mainly enzymes) and small, mostly exogenous, molecular compounds, acting as free radical scavengers (Saito & Takahashi, 2000; Stanczyk et al., 2005) .
In aerobic organisms several enzymes are involved in scavenging free radicals:
superoxide dismutases (SOD; EC 1.15.1.1), catalases (Cat; EC 1.11.1.6), glutathione peroxidases (GSH-Px; EC 1.11.1.9) (Joseph, 1995; Grignard et al., 2005) and probably selenoprotein P (Saito & Takahashi, 2000; Burk & Hill, 2005) . The reactions catalyzed by these enzymes are presented in Fig. 1 . (Young & Woodside, 2001 ).
In mammalian tissues, there are at least three distinct superoxide dismutase isoenzymes, including one manganese form (Mn-SOD) present in the mitochondrial matrix and two copper and zinc forms (Cu,Zn-SOD), one of which is in the cytosol and the other in various extracellular fluids (Fantel, 1996; Young & Woodwide, 2001) . Superoxide dismutases play a key role in catalyzing the dismutation of O 2
•−
to O 2 and H 2 O 2 . Catalase or GSH-Px must then remove the hydrogen peroxide formed. In the presence of transition metals, H 2 O 2 can be reduced (in the metal-catalyzed Haber-Weiss reaction) to the extremely reactive • OH (Fantel, 1996) . In many tissues, catalase activity, largely localized to peroxisomes, is very low and frequently not available for decomposition of H 2 O 2 . Therefore, in most tissues, H 2 O 2 decomposition is obtained by GSH-Px (Joseph, 1995) . This enzyme catalyzes the reduction of H 2 O 2 and a wide range of organic hydroperoxides (ROOH) to water and corresponding alcohols (ROH), respectively. They are very specific for glutathione (GSH) as the reducing substrate (Patching & Gardiner, 1999; Arthur, 2000) . The enzymes involved in the scavenging of free radicals catalyze the following reactions:
SelenIum In blOOD COmPOnenTS AnD In uRIne Selenium in blood components and Se metabolites in urine of healthy individuals
Kidneys play an important role in the homeostasis of selenium (Se) (Lockitch, 1989; Neve, 1991) . When Se is consumed at rates close to the human nutritional requirement, its highest level is found in kidneys and then in the liver (Combs & Combs, 1984) . It has been shown that the amount of Se in the kidney, calculated per wet mass, is 1.4 to about 3 times higher than in the liver and 6.6 to 10 times higher than in skeletal muscles (Zachara et al., 2001b) . The Se level in tissues/organs depends on its daily intake, the chemical form of ingested Se and probably on other unknown factors (Lockitch, 1989; Alaejos & Romero, 1993 ). Thus the tissue Se level in people from seleniferous regions is much higher than in those living in low Se areas (Zachara et al., 2001b) .
The predominant route of Se excretion in the healthy human is urine and feces (Robberecht & Deelstra, 1984; Alaejos & Romero, 1993) . Se losses in urine represent 50-70% of the ingested element. At high or low levels of intake, more or less Se is excreted with urine. Yang et al. (1989) studied the relation between Se intake and 24-h urinary Se excretion in Chinese living in regions with low (66.3 µg), medium (196 µg) and high (1338 µg) daily dietary Se intake and found a linear, highly significant correlation (r = 0.886; P < 0.001) between those parame- Alaejos & Romero, 1993) . In 1969, Byard was the first to identify a urinary Se metabolite as trimethylselenonium ion (TMSe). Almost at the same time Palmer et al. (1969; 1970) identified TMSe as the major Se metabolite in rat urine. These authors have shown that TMSe is a common urinary metabolite from all tested Se sources and constituted 20-50% of the urinary Se. The TMSe level in urine has been generally thought to increase when Se exposure is above the nutritional requirement. This Se metabolite was later found in human urine (cf. Francesconi & Pannier, 2004) . Se metabolism in mammals and its transformation into methylated forms are shown in Fig. 2 . (Medina et al., 2001) .
1) O
Recent analytical advances based on HPLC separations coupled with atomic and molecular mass spectrometric detection have provided new insights into Se metabolites in urine (Francesconi, 2006) . In particular, novel Se-containing selenosugars are now known to be major urinary metabolites in humans and in rats, and TMSe is now considered to be a less significant metabolite (Francesconi & Pannier, 2004; Suzuki et al., 2005) . Among them a metabolite called selenosugar 2 (methyl-2-acetamido-2-deoxy-1 seleno-β-d-galactopyranoside) has been identified (Kobayashi et al., 2002; Francesconi & Pannier, 2004; Suzuki, 2005; Suzuki et al., 2005) . Two other selenosugars (1 and 3) have been identified in lower levels (Kobayashi et al., 2002; Francesconi & Pannier, 2004) . Suzuki et al. (2005) have shown that in young rats supplied with the required to low toxic levels of Se, selenosugar was always the major urinary metabolite. TMSe starts to increase in urine with excessive Se intake. In adult rats, TMSe is present only as a minor metabolite and thus it cannot be a marker of excessive Se intake. Kuehnelt et al. (2006) have recently shown that in volunteers supplemented with 200 µg Se as selenite, TMSe was present in trace amounts (0.02 to 0.28 µg Se/L; equivalent to 1-5% Se in urine), while selenosugars ranged from 4.6 to 15 µg Se/L (22 to 53% of Se in urine). The precise mechanisms by which diverse nutritional selenocompounds are transferred to common intermediate selenide, then selenide to selenosugars and TMSe, are not known (Suzuki, 2006) .
Selenium in blood components of chronic kidney disease patients
Although some investigators did not find any difference between CKD patients and healthy subjects regarding whole blood or plasma Se concentrations (Tsukamoto et al., 1980; Lockitch, 1989; Milly et al., 1992) , significantly lower values have been more often shown in the former group (Dworkin et al., 1987; Foote et al., 1987; Richard et al., 1991; Girelli et al., 1993; Ceballos-Picot et al., 1996; Yoshimura et al., 1996; Vural et al., 2005; Zachara et al., 2000a; 2001c) . Several authors have found that in non-dialyzed CKD patients the overall plasma Se concentration from incipient to the end-stage of the disease is by 12.5-44.1% lower than in healthy subjects (Kallistratos et al., 1985; Richard et al., 1991; Girelli et al., 1993; Loughrey et al., 1994; Ceballos-Picot et al., 1996; Zachara et al., 2000a) . Zachara et al. (2000b) reveal that in the early stage of the disease, Se concentration in whole blood and plasma does not significantly differ from the value of the control group. Similar results have been presented by Ceballos-Picot et al. (1996) . Along with the progression of the kidney impairment, Se concentration decreases in whole blood and plasma. This was particularly evident in the end-stage of the disease, where Se concentration in whole blood and plasma was lower by 47 and 50%, respectively (P < 0.0001) as compared with the control group (Zachara et al., 2000b) . In the entire group of CKD patients, weak but significant negative correlations were found between plasma Se and plasma creatinine levels (r = -0.380; P < 0.0001) as well as between plasma Se and plasma urea nitrogen levels (r = -0.348; P < 0.0001) (Zachara et al., 2004b) . Higher negative correlations were found by Ceballos-Picot et al. (1996) and Yoshimura et al. (1996) . In patients on hemodialysis (HD), plasma Se concentration was also significantly lower than in healthy subjects, and the degree of the reduction was very often similar to that in non-dialyzed patients (Kallistratos et al., 1985; Dworkin et al., 1987; Foote et al., 1987; Kuroda et al., 1988; Saint-Georges et al., 1989; Richard et al., 1991; Girelli et al., 1993; Bonomini et al., 1996; Ceballos-Picot et al., 1996; Lachili et al., 1996; Yoshimura et al., 1996; Zachara et al., 2000a) . Dworkin et al. (1987) have shown that in patients undergoing continuous ambulatory peritoneal dialysis (CAPD), Se concentration in blood components was significantly lower than in HD patients. The lower blood Se level in CAPD patients probably reflects a greater protein leak across the peritoneal membrane as compared with HD patients (Dworkin et al., 1987) . However, Girelli et al. (1993) have not found any difference between plasma Se concentration in CAPD and HD patients, while Zima et al. (1998) found this concentration higher in CAPD than in HD patients. Further studies on a larger group of patients are required to elucidate the discrepancies.
Several authors measured the effect of dialysis on the Se level in blood components. It has been shown that after dialysis, Se concentration in plasma/serum increases by 5.5-20.3%, however, in some studies this increment was insignificant (Dworkin et al., 1987; Bonomini et al., 1996) , while in others it was statistically proved (Milly et al., 1992; Lachili et al., 1996) . Surprisingly, the measurement of Se concentration in whole blood did not reveal any differences (Dworkin et al., 1987; Milly et al., 1992) , which means that the observed differences mostly apply to Se present in serum/plasma, but probably not in red blood cells. It is well known that about 95% of Se present in plasma is found in proteins (MarchanteGayon et al., 1996) . These compounds, being macromolecules, do not penetrate membranes and thus cannot be removed from the organism during HD.
It has been experimentally documented that Se present in plasma is incorporated into GSH-Px and selenoprotein P as selenocysteine (SeCys), or bound to albumin in the form of selenomethionine (SeMet) (Deagan et al., 1993) . A small amount of Se is present in micromolecules with unknown structure and function (Marchante-Gayon et al., 1996) . Deagan et al. (1993) showed that in human plasma, irrespective of Se concentration (from 21 to 162 ng/ mL), the mean incorporation/binding of this element into selenoprotein P, GSH-Px and albumin was 57, 20 and 23%, respectively. Read et al. (1990) showed exactly the same value for selenoprotein P: about 60% of Se present in plasma is incorporated into this protein. Dworkin et al. (1987) found a positive, significant correlation between whole blood Se concentration and serum albumin level in dialyzed patients.
The correlation was even stronger when HD plus CAPD patients and healthy subjects were combined (r = 0.61, P < 0.001). Similar results have been presented recently by Zachara et al. (2004b) , who demonstrated significant correlations between plasma total protein and Se concentration (r = 0.299) as well as between albumin and Se levels (r = 0.326) in nondialyzed CKD patients. In another study the same group of researchers (Zachara et al., 2004a) showed a positive correlation between plasma total protein and plasma Se concentration as well as between plasma albumin and Se levels in HD patients. After combining the values of HD patients and controls, these correlations reached a higher level of significance (r = 0.406, and r = 0.456, respectively; P < 0.0001 in both cases).
Several mechanisms have been reported to explain the altered Se status in uremic patients. The supposed mechanisms comprise (Bonomini & Albertazzi, 1995) : decreased dietary intake, increased urinary or dialytic losses, impaired intestinal absorption, abnormal binding to Se transport proteins or drug therapy. It seems very likely that the main reason for the decreased Se concentration in CKD patients is low protein intake and increased protein loss with urine (Lockitch, 1989; Allan et al., 1999) . CKD patients are frequently advised to limit protein consumption (Zachara et al., 2004b) . Since protein foodstuffs contain the largest amount of Se (Bonomini & Albertazzi, 1995; Olson & Palmer, 1999) , reduced protein intake has been suggested as a substantial cause of Se deficiency (Bonomini & Albertazzi, 1995) .
ReD Cell AnD PlASmA GluTATHIOne PeROxIDASeS
In general, trace elements function as prosthetic groups of enzymes and Se is an essential component of at least 25 selenoproteins, which have been partially or fully characterized (Burk et al., 2003; Kryukov et al., 2003; Kohrle, 2004; Wastney et al., 2006) . Among the five distinct GSH-Pxs identified so far in mammals (Behne & Kyriakopoulos, 2001) , each contains Se in the form of one SeCys residue per subunit or molecule (Arthur, 2000; Behne & Kyriakopoulos, 2001) . Two forms have been identified in blood: cellular (also called cytosolic or classical, GSH-Px 1) present in red blood cells, and extracellular (GSH-Px 3) present in plasma (Arthur & Beckett, 1994) . The activity of cellular GSH-Px was first described by Mills in 1957 and the enzyme was shown to protect red blood cells against hemoglobin oxidation and hemolysis (Mills, 1957) . In 1973, Rotruck et al. (1973) in the United States and Flohe et al. (1973) in Germany independently found that
Selenium and glutathione peroxidases in patients with chronic kidney disease
Se is an integral structural component of the active site of red blood cell GSH-Px. GSH-Px 1 is the most extensively characterized selenoprotein, being found in erythrocytes and cytosol of nearly all tissues of mammals, birds and several other organisms (Zachara, 1992; Behne & Kyriakopoulos, 2001) . It is a tetrameric protein with four identical subunits of 19-24.8 kDa each, depending on the species and tissues examined, with one gram atom of Se in the form of SeCys per subunit (Zachara, 1992) . Selenium supplementation has been shown to increase the tissue and red cell protein content of GSH-Px and enzyme activity in HL-60 cells, laboratory animals, livestock and humans . The effect of dietary Se intake on GSH-Px in erythrocytes is apparent and lasts about 100-120 days, which corresponds closely with the life span of these cells and suggests that Se is incorporated into the enzyme only during erythropoiesis.
Another enzyme present in blood is plasma GSH-Px that shows a significant diagnostic value in kidney diseases. Investigating Se deficiency in humans, Cohen et al. (1985) found that after Se supplementation of Se-deficient individuals, plasma GSHPx activity returned to normal values within 4-5 weeks, whereas 3-4 months were required for the red blood cell enzyme to reach this effect. have shown that rabbit polyclonal antibodies prepared against purified human red cell GSH-Px precipitate all of the human red cell GSHPx while plasma GSH-Px is not precipitated. This observation suggests that plasma GSH-Px is distinct from the red cell enzyme. Further studies of purified plasma GSH-Px (Takahashi et al., 1987; Zachara, 1992) have shown that this enzyme is structurally, enzymatically and antigenically different from that in erythrocytes and other cells. Plasma GSH-Px, like the red cell enzyme, has a tetrameric form with identical subunits of about 21.5-23.0 kDa, with four gram atoms of Se (as SeCys) per mole of the enzyme (Takahashi et al., 1987; Zachara, 1992) . As expected for plasma proteins, GSH-Px 3 is a glycoprotein (Takahashi et al., 1987) . It has been shown that in humans, plasma GSH-Px is synthesized primarily in the proximal tubular cells of the kidney (Avissar et al., 1994) . Along with the kidney, this enzyme is also synthesized in the liver, lung, heart, breast, intestine, brain, skeletal muscle and placenta, from which it is secreted into the extracellular fluid (Chu et al., 1992; Avissar et al., 1994; Behne & Kyriakopoulos, 2001) .
Glutathione peroxidases in blood of patients with chronic kidney disease
Decreased Se concentrations and GSH-Px activities in blood components are common symptoms in CKD patients, especially in the end-stage renal disease . Results of studies on the activity of red blood cell GSH-Px in CKD patients are inconsistent. Numerous authors report significantly lower (Richard et al., 1991; Roxborough et al., 1999; Zachara et al., 2000a; 2001c) or significantly higher activity (Ceballos-Picot et al., 1996) , whereas others show similar activities, lower or higher, but not significantly different from those observed in healthy controls (Yoshimura et al., 1996; De Vega et al., 2002; Sommerburg et al., 2002; Zachara et al., 2004a; Stachowska et al., 2005) . Zwolinska et al. (2004) have recently revealed that red cell GSHPx activity is significantly lower in children with CKD than in age-matched healthy children, but it is the same in moderate and advanced stages of the disease. On the other hand, Sommerburg et al. (2002) found that red cell GSH-Px activity in children with end-stage CKD was almost twice as high as in agematched controls (23.3 vs. 13.8 U g/Hb). In contrast, in adult end-stage CKD patients the activity of this enzyme was significantly lower than in children and the same as in healthy subjects (14.0 vs 15.1 U/g Hb).
The authors think that the higher activity of GSH-Px in CKD children may possibly reflect the presence of an adaptation mechanism by which their antioxidant system is enhanced and adapted to the conditions of oxidative stress. Several authors (CeballosPicot et al., 1996; Zachara et al., 2004a; 2004b) have shown that, like in children (Zwolinska et al., 2004) , red cell GSH-Px activity in adult CKD patients did not differ significantly between various stages of the disease, regardless of whether it is lower (Zachara et al., 2004b) , higher (Ceballos-Picot et al., 1996) or the same (Zachara et al., 2004a) as compared with controls. This means that the synthesis of this enzyme during erythropoiesis in uremic patients is not impaired. The red blood cell GSH-Px activity in various stages of CKD is presented in Fig. 3 (Zachara et al., 2004b) .
The red blood cell GSH-Px activity depends on blood Se concentration (Richard et al., 1991) , and increases in Se-supplemented CKD patients (SaintGeorges et al., 1989; Richard et al., 1993; Hussein et al., 1997; Koenig et al., 1997) . Like in healthy subjects (Zachara, 1992; Iwanier & Zachara, 1995) , the activity of this enzyme increases progressively in CKD patients and reaches a plateau after about 13 weeks (Richard et al., 1991; . Richard et al. (1991) found a high and significant correlation (r = 0.66; P < 0.005) between plasma Se concentration and red cell GSH-Px activity in HD patients. In contrast, Yoshimura et al. (1996) did not find any correlation between these two parameters. Since the low Se level in CKD patients is associated with an increased incidence of malignancy (Lindner et al., 1981; Kallistratos et al., 1985; Vamvakas et al., 1998) and cardiovascular diseases (Amann & Tyralla, 2002;  Go et al., 2004) , Se supplementation may prove to be beneficial in preventing these diseases (Bonomini & Albertazzi, 1995) .
In CKD patients, plasma GSH-Px synthesis and activity seem to be much more important than the red cell enzyme. Therefore, we would like to concentrate our attention primarily on the extracellular GSH-Px. Studies on this enzyme have shown that although GSH-Px 3 is synthesized in different tissues (Chu et al., 1992) , renal proximal tubular epithelial cells are the main source of the enzyme in plasma (Avissar et al., 1994; Whitin et al., 1998) .
It has been shown that kidney has a high concentration of GSH, therefore plasma GSH-Px may have a specific antioxidant function in renal tubules and/or in extracellular spaces (Brown & Arthur, 2001) . GSH, a substrate of GSH-Px, is the most abundant antioxidant inside the cell, where it occurs in a relatively high concentration (Stanczyk et al., 2005) . It is the main intracellular defense mechanism against oxidative stress damage, and being a free-radical scavenger, it is directly involved in the reduction of superoxide anion (Vanella et al., 1983) . It performs a variety of physiological and metabolic functions, including detoxification reactions against free radicals and toxic compounds (Meister, 1984; Ceballos-Picot et al., 1996) . GSH levels in blood of CKD patients vary in different studies. Some authors found the levels unchanged (Mimic-Oka et al., 1991; Canestrari et al., 1994; Pasaoglu et al., 1996) , others lower (Vanella et al., 1983; Ceballos-Picot et al., 1996; De Vega et al., 2002) or higher (Cristol et al., 1998; Zachara et al., 2001a) than in healthy controls. Ceballos-Picot et al. (1996) showed that this tripeptide decreased along with the progress of the disease, which in their opinion could be attributed to a reduced synthesis and/or increased degradation. The authors reporting higher levels of GSH in CKD patients indicated that the elevated concentration was maintained during all stages of the disease, which in turn could be recognized as a cell protective mechanism by which the decreased activity of plasma GSH-Px is compensated and thus involved in scavenging of free radicals (Zachara et al., 2001a) .
In contrast to the differences in red cell GSHPx activity in CKD patients, found in reports of various authors, plasma GSH-Px activity has always been shown to be reduced by 34-52% as compared with healthy subjects (Richard et al., 1991; Schiavon et al., 1994; Ceballos-Picot et al., 1996; Yoshimura et al., 1996; Cristol et al., 1998; Zachara et al., 2004b; Zwolinska et al., 2004) . Several authors have indicated a gradual decrease in the activity with advancing stage of the disease (Ceballos-Picot et al., 1996; Yoshimura et al., 1996; Zachara et al., 2004b ). An example is shown in Fig. 3 (Zachara et al., 2004b) . The presence of a negative, statistically significant correlation between plasma GSH-Px activity, creatinine clearance and creatinine concentration (Ceballos-Picot et al., 1996; Yoshimura et al., 1996; Zachara et al., 2004b) as well as between plasma GSH-Px activity and urea nitrogen concentration in plasma (Zachara et al., 2004b) was revealed. In the end-stage CKD, the activity of this enzyme decreased to 34% of the value observed in the control group. A progressive decline in plasma GSH-Px activity is linked with the fact that this enzyme is primarily synthesized in the kidney (Avissar et al., 1994; Whitin et al., 1998) and -as generally believed -the progressing damage of this organ is reflected in diminished enzyme activity. Ceballos-Picot et al. (1996) have shown that in HD patients, plasma GSH-Px activity is significantly lower than in non-dialyzed patients with severe CKD and almost completely abrogated (8.9 U/mL) as compared with controls (71.0 U/mL). Martin-Mateo et al. (1998; demonstrated that in CKD patients, plasma GSH-Px activity was lower by about 50% than in healthy persons. In their opinion this decline might be associated with a lower enzyme pro- Patients were divided according to plasma creatinine (cr.) level: group I, incipient (n = 55) with cr. up to 1.36 mg/dL; group II, moderate (n = 40) with mean cr. level 1.72 mg/dL; group III, advanced (n = 40) with mean cr. level 3.96 mg/dL; group IV, end stage (n = 15) with mean cr. level 4.87 mg/dL. Statistics: *, P < 0.01 vs. control; **, P < 0.0001 vs. control (taken from Zachara et al., 2004b) .
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duction in the kidney. They also showed (MartineMateo et al., 1999) that after HD session, the enzyme activity increased by 20% as compared with the pre-HD value. Roxborough et al. (1999) found that after HD plasma GSH-Px activity increased and reached the value observed in the control group. Both teams (Martin-Mateo et al., 1999; Roxborough et al., 1999) thought that the decreased activity might be attributed, at least in part, to the inhibition caused by ligands or toxic agents of endogenous nature. These inhibitors are most likely removed by dialysis.
As already mentioned, supplementation of healthy persons with selenium leads to an increase in GSH-Px activity in red cells, plasma and other body fluids (Iwanier & Zachara, 1995; . The results of studies of the effect of Se supply on plasma GSH-Px activity in CKD patients, reported by various authors, are inconsistent. Although a significant increase in plasma Se concentration in this group of patients has been observed (Richard et al., 1993; Zachara et al., 2000a; 2004a) , some authors have indicated statistically significant increase in this enzyme's activity (Saint-Georges et al., 1989; Bellisola et al., 1993; Richard et al., 1993) , whereas others have noticed no substantial differences (Zachara et al., 2000a) . Richard et al. (1993) and Saint-Georges et al. (1989) have shown that plasma GSH-Px activity rose significantly after Se supplementation and reached a plateau after 3-4 months, but it was still lower than in healthy subjects. These discrepancies seem to be associated with the degree of kidney damage in individual study groups of patients. If the patients under study were in the incipient stage of CKD, Se supply induced synthesis of this enzyme in the kidney, which was demonstrated by an increase in its activity. In more advanced stages of the disease, the body response to Se supply, due to a greater kidney damage, was much weaker or totally absent. Some authors (Zachara et al., 2004a) observed that in CKD patients supplemented with 200 µg Se/day for 3 months plasma GSH-Px activity increased significantly in the whole group, but particularly in patients in the incipient stage of the disease (creatinine level up to 2.5 mg/dL), and did not change significantly compared with its pretreatment values in the advanced stage of the disease (creatinine level > 4.5 mg/dL (Fig. 4) .
A full agreement on whether a decreased plasma GSH-Px activity or a decreased synthesis of this enzyme occurs in CKD patients has not been reached yet. Ceballos-Picot et al. (1996) think that the progressive decline in plasma GSH-Px activity results from a gradual damage of an active part of nephron responsible for the biosynthesis of this enzyme. To clarify the existing doubts whether a decreased activity or a decreased biosynthesis of this peroxidase does occur, Yoshimura et al. (1996) simultaneously determined the activity and concentration of plasma GSH-Px protein in several nondialyzed patients. In the study group, the enzyme activity was by over 50% lower than in the control group, whereas the protein concentration, measured using anibodies against plasma GSH-Px, was almost below the level of sensitivity or its detection was not possible. The authors conclude that the diminished activity of this enzyme in plasma of the patients was associated with low concentration of the plasma GSH-Px protein. However, it should be noted here that in humans a small amount of plasma GSH-Px is synthesized not only in the kidney (Avissar et al., 1994) , but also in several other organs (Chu et al., 1992) . The results of the study reported by Yoshimura et al. (1996) show that the decreased concentration of plasma protein GSH-Px may be associated with an impaired biosynthesis of this enzyme in the kidney. In other words, the damaged kidney is able to synthesize only a small amount of the protein, or its synthesizing ability is completely lost. The possibility of an enhanced catabolism of GSH-Px in CKD patients cannot be ruled out. The authors made some other important observations. As it had been previously thought that the diminished activity of plasma GSH-Px in CKD patients could be linked with Se deficiency (Richard et al., 1991) , Yoshimura et al. (1996) determined plasma Se concentration and GSH-Px activity in red cells. They found in their patients normal Se concentration and higher GSHPx activity in red cells compared with the control group. Another group of researchers (Ceballos-Picot et al., 1996) showed that in CKD patients, plasma Se concentration gradually and significantly decreased with advancing stage of renal failure, while GSH-Px activity in red cells was significantly higher than in controls and was maintained at the same level in all stages of the disease as well as in HD patients. Therefore, the authors (Ceballos-Picot et al., 1996; Yoshimura et al., 1996) conclude that the diminished plasma GSH-Px activity is not linked with Se deficiency in blood. A similar opinion was expressed by other authors (Zachara et al., 2000a; 2004b) on the basis of their own studies.
As to the concentration of the plasma GSHPx protein, Roxborough et al. (1999) presented the results completely opposite to those reported by Yoshimura et al. (1996) . They obtained specific antibodies to human plasma GSH-Px, and determined, by applying the ELISA test, the GSH-Px protein in plasma of controls and patients on hemodialysis. They made two observations. First, the activity of this enzyme in pre-HD patients was over 50% lower than in healthy controls and it significantly increased in post-HD patients, but did not reach the values recorded in the control group. Second, plasma concentration of GSH-Px protein was the same before and after hemodialysis and -which is extremely important -its values did not differ from those observed in healthy controls. The problem of plasma GSH-Px synthesis in CKD patients has not been unequivocally elucidated yet.
Bearing in mind that plasma GSH-Px activity is diminished in all CKD patients, in our opinion the determination of GSH-Px 3 activity in these patients may have certain diagnostic value, which means that this enzyme can be recognized as an additional marker useful in assessing the degree of CKD advancement; the lower the enzyme activity the more advanced the disease stage.
Glutathione peroxidases in blood of patients after kidney transplantation
Kidney transplantation is now the only treatment that may restore plasma GSH-Px in patients afflicted with end-stage CKD. The data on Se concentration and GSH-Px activities in blood of patients after kidney transplantation are still rather scarce. To the best of our knowledge, there are three different groups of researchers reporting the results on the antioxidant status (mainly plasma GSH-Px) in patients in early stages after kidney transplantation: one in the United States (Avissar et al., 1994; Whitin et al., 1998) , one in Spain and one in Poland (Zachara et al., 2004c; 2005; Wlodarczyk et al., 2005) . In the early 1990s, Avissar et al. (1994) , searching for the source of plasma GSHPx, studied the activity of this enzyme in serum and plasma of seven anephric patients. They found that the activity was 22.6% of that noted in the four matched controls and was also significantly lower than plasma GSH-Px activity in HD patients. In addition, the authors examined GSH-Px activity and Se concentration in plasma of 96 HD patients and in 11 controls. Patients plasma Se levels were within the normal range, while GSH-Px activity of the HD patients was 42% of the activity of the control group (P < 0.001). The authors proved that the reduction in plasma GSH-Px activity could not be attributed to the lowered Se concentrations because: 1) the Se level in the patients' plasma was not significantly different from that in controls (118 vs. 130 ng/mL, respectively); 2) when the patients were divided into two subgroups by Se levels (11 persons with the level < 96 ng/mL, and 12 with the level > 138 ng/mL), there was no significant difference in their plasma GSH-Px activity (0.129 and 0.159 U/mL, respectively); and 3) the patients showed high (142% of the control value) red blood cell GSH-Px activity. In sera of three transplanted patients, Se levels and GSH-Px activities were measured 22 and 30 days after surgery. Se level was the same as prior to transplantation, while the plasma GSH-Px activity was eight times higher than before surgery and two times higher than in controls. Several months after transplantation, the plasma GSH-Px activity returned to normal values of healthy persons. These results suggest that the kidney supplies a major portion of plasma GSH-Px activity. The authors have also shown the absence of an inhibitory effect of anephric plasma on GSH-Px activity in the control plasma: there was no inhibition of GSH-Px activity of normal plasma on addition of plasma from anephric patients. Thus the authors: 1) rule out the inhibitory effect of plasma metabolites or uremic toxins on the enzyme activity; and 2) indicate that the lowered Se level is not a limiting factor for GSH-Px synthesis. These two facts are very often suggested by some authors to be the cause of the lowered plasma GSH-Px activity in CKD patients.
Four years after the previous transplantation, Whitin et al. (1998) , from the same center, transplanted kidneys in three groups of patients: 1) sixteen adults with renal disease who received a kidney transplant from related donors; 2) six adult patients who received cadaveric kidney transplants; and 3) three pediatric patients undergoing bilateral nephrectomy with subsequent kidney transplanta-Selenium and glutathione peroxidases in patients with chronic kidney disease tion from related donors. Before transplantation, the HD patients had the plasma GSH-Px activity of 34% (group 1) and 50% (group 2) of the control plasma, while the anephric individuals (group 3) had the plasma GSH-Px activity ranging from 2 to 24% of that recorded in controls. After transplantation, the plasma GSH-Px activity increased very rapidly: in group 1, the enzyme activity was two times higher three days after transplantation than before operation, and 21 days post-transplant the averaged activities were within the normal values. In group 2, the plasma GSH-Px activity increased rapidly over the first two weeks post kidney transplant. In six patients of this group, plasma GSH-Px activity reached the normal level after 9.8 days, and 27 days post-transplant the plasma enzyme activity reached a maximum level -144% of the control value. The maximum level was temporary and after several weeks it decreased to a range similar to that of healthy individuals. In two patients of group 3, plasma GSH-Px activity increased rapidly within two weeks following kidney transplantation, while in the third patient this period was quite longer. The data presented by the authors show that in patients undergoing kidney transplantation, plasma GSH-Px activity increases rapidly -within 2 weeks posttransplant.
Quite recently Zachara et al. (2004c) have shown that in 30 patients before kidney transplantation the Se concentration in whole blood and plasma was lower by about 20% as compared with controls (P < 0.0001) and within a week after operation it significantly decreased. The reason for the decrement just after operation was not known but could probably be linked with the restricted diet of the operated patients and thus with the extremely low Se intake. During the first 36-48 h after surgery, the patients received only intravenous and oral fluids containing no protein -the main source of Se. From the second day, a diet, containing progressively up to 70 g of protein, was being introduced, so that the Se level increased slowly, but even 3 months following transplantation it was still significantly lower than in healthy subjects. Zachara et al. (2004c; 2005) have shown that before transplantation as well as within a 3-month period after surgery the red cell GSH-Px activity in the patients was the same as in healthy controls. However, plasma GSH-Px activity before transplantation (75.6 U/L) was by 69% lower in patients than in the control group (243 U/L, P < 0.0001), after 3 days it increased rapidly to 115 U/L, and 2 weeks after surgery it doubled (164 U/L) the initial value (P < 0.0001). Unlike to other authors (Avissar et al., 1994 , Whitin et al., 1998 , 3 months after transplantation the activity was still significantly lower than that of the control group (Zachara et al., 2004c) . The authors also showed that in transplanted patients who were not dialyzed after surgery (n = 7), or were dialyzed only once just after surgery (n = 4) (subgroup 1), the plasma GSH-Px activity, throughout a 3-month period, was significantly higher (0.001 < P < 0.05) than in patients who had 2-11 HD sessions (n = 19) (subgroup 2). On the contrary, between day 3 and day 30 after transplantation, creatinine concentration was significantly lower in subgroup 1 (0.0001 < P < 0.01) than in subgroup 2. Although there is as yet no conclusive explanation for the disparate results of this observation, the authors speculate that immediate or delayed assumption of function of the transplanted kidney could be the main causative factor (Zachara et al., 2004c) . Therefore, monitoring of plasma GSHPx activity may be an additional useful marker for the transplanted kidney function.
Selenium supplementation to kidney transplant recipients has a positive effect on the antioxidant system. Hussein et al. (1997) have shown that treatment of allograft recipients with 200 µg Se/day results in a reduction in drug-induced plasma lipid peroxidation, a significant elevation of GSH content as well as of red cell GSH-Px and glutathione reductase activities. Wlodarczyk et al. (2005) have Figure 5 . Plasma glutathione peroxidase activity in control group and in patients before and after kidney transplantation supplemented and nonsupplemented with Se. Statistics: a, P < 0.0001 vs. control group; b, P < 0.01 vs. initial values (in both groups taken separately); c, P < 0.0001 vs. initial values (in both groups taken separately); d, P < 0.01 vs. supplemented and non-supplemented patients (taken from Wlodarczyk et al., 2005) . (1992) found that in 30 transplanted patients, 5-53 months (mean, 19.9) after surgery, the mean plasma Se concentration was higher by 35% (P < 0.0001) as compared with controls. Wlodarczyk et al. (2003) found no changes in red cell GSH-Px activity in kidney transplanted patients just after surgery and within a 6-month period following operation; the values were the same as in controls. Juskowa et al. (2000) have shown that in patients who, after kidney transplantation, were treated for 4 years with triple-drug therapy (prednisone, azathioprine and cyclosporine A), red cell GSH-Px activity was significantly lower (P < 0.02), while in patients treated with two drugs only (without cyclosporine A), the activity after 10.8 years was the same as in controls. Cyclosporine A is known as a nephrotoxic drug, induces the production of ROS (Kasiske, 2002) . In contrast, Simic-Ogrizovic et al. (1998) have shown that in patients treated with triple-drug therapy (the same as in Juskowa et al., 2000) , 5 years after kidney transplantation, the red cell GSH-Px activity in transplant recipients with stable kidney function was higher by 28%, whereas in a group of patients with chronic rejection it was higher by 63% as compared with controls.
Selenium and glutathione peroxidases in patients with chronic kidney disease
There are contradictory data on plasma GSHPx activity in kidney recipients several months to several years after transplantation. Some authors found significantly lower plasma GSH-Px activity 5 years after operation (Turan et al., 1992) , and -since they found high cadmium concentration in sera -they thought that this metal with a high affinity for the -SH groups of the enzyme might inactivate GSH-Px. Kim et al. (2000) showed that 32.4 months after kidney transplantation plasma GSH-Px activity was the same as in the control group although the MDA level was significantly higher in transplant recipients. Similar results were presented by other authors (Simic-Ogrizovic et al., 1998) : in patients with stable kidney function, 5 years following kidney transplantation, although the MDA level in plasma was 4 times higher than in controls, plasma GSH-Px activity did not differ between those two groups. On the other hand, in kidney recipients with histologically proven chronic rejection, the MDA level was 3 times higher than in controls, while plasma GSH-Px activity was lower (24.7%; P < 0.05) than in healthy subjects. The authors (Kim et al., 2000) thus think that the significantly lower plasma GSH-Px activity in patients with chronic rejection symptoms was most probably a consequence of impaired production of GSH-Px in the transplanted kidney. This opinion contradicts the data of Cristol et al. (1992; 1996) who showed that in kidney recipient patients, both in stable function and chronic rejection, the level of plasma GSH-Px protein was significantly higher (by 109-112% and 32-61%, respectively) than in healthy volunteers. The significant increase in plasma GSH-Px protein level could result from an induction of GSH-Px synthesis. The patients with stable function of the transplanted kidney are able to synthesize more enzyme than those with an impaired kidney function.
In conclusion, Se concentration in whole blood and plasma of CKD patients is very often lower than in healthy controls. Several to a dozen months after kidney transplantation, Se concentrations in whole blood and plasma return to normal values. The red blood cell GSH-Px activity in CKD patients is usually unchanged although some authors found lower or higher values. Plasma GSH-Px activity is always reduced and the reduction increases with increasing stage of the disease. In Se-supplemented CKD patients plasma GSH-Px activity rises slightly in the early stages of the disease and remains unchanged in end-stage CKD. After kidney transplantation, plasma GSH-Px activity increases very rapidly and several months -years after surgery it is usually the same as in healthy subjects. Measurement of plasma GSH-Px activity in CKD patients and in transplant recipients may be an additional marker in the diagnosis of the stage of uremia or the function of the transplanted kidney. The data show that the kidney plays an important role in Se homeostasis and is the predominant source of plasma GSH-Px.
